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Abstract  
 
Breast cancer is one of the most common and heterogonous cancer types, and the first 
cause of death related to cancer in women worldwide. Breast cancer is triggered by 
endogenous and/or exogenous factors. These factors lead to critical mutations and/or 
eipmutations in important genes including oncogenes and tumor suppresser genes.  These 
genetic and epigenetic changes lead to cancer initiation and cancer progression. During 
these processes, cells gain alteration and dysregulation in gene expression at different 
levels. The most important and critical level of gene expression alteration in cancer is the 
transcriptional level.  
 
Our current project is part of a larger project, in which we hypothesized that breast cancer 
transformation might have common transcriptional reprograming events, that are 
associated with misregulation in gene expression, which reflects on cellular activity and 
homeostasis. In this part of the project, the aim was to test the ability to generate a proof of 
concept breast cancer transformation model that can be used to study transcriptional 
reprogramming in breast cancer and identify specific TFs that can be used as biomarkers 
for diagnosis, prognosis or even treatment of breast cancer. An in vitro breast cancer 
transformation model using HRAS overexpression in immortalized non transformed 
normal epithelial mammary gland cells (MCF10A) was generated. After HRAS 
overexpression, different cell phenotypes were tested, known to be induced by HRAS 
overexpression, that in order to ensure successful transformation. the transformed cells 
were then tested (not by us in this part of the project), for transcriptional reprogramming. 
Using different techniques, the model, indeed, showed massive genome wide 
transcriptional re-programming. Among the different transcription site activities that were 
lost are transcription sites of p53 and p63. In order to evaluate the role of these 
transcription factors in this transformation model, the functions of these two important TFs 
(p53 by using Nutlin-3a, and p63 by its overexpression) were reactivated. Our results, 
showed that the induction of these TF functions was enough to revert to certain extent 
some the transformation process-related phenotypes.   
 
V 
 
In conclusion, our transformation model can be used as an efficient tool to learn about 
transcriptional re-programing during cellular transformation, to identify and study the role 
of specific TFs in transformation. This may contribute to identifying some target genes 
involved in breast carcinogenesis and employ them in prognosis, diagnosis and treatment.   
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Chapter 1 
ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
1. Introduction  
 
1.1. Cancer 
 
Cancer is a multifactorial disease. It can be initiated by multiple exogenous and endogenous 
factors. Exogenous factors including physical factors, like ionizing or UV irradiations, 
chemical factors, like cigarette smoking and industrial waste products, and biological factors, 
like different types of viruses and bacteria. Endogenous factors include metabolic and 
hereditary risk factors. regardless the nature of the carcinogenic factor,  it must cause  critical 
mutations in oncogenes such as RAS and PIK3CA or tumor suppressor genes such as p53 and 
pRb or both (Ritchie et al., 2001). These mutations eventually induce tumorigenesis 
progression through diverse genetic and epigenetic alteration that drive the transformation of 
normal cells into malignant derivatives. This diversity results in different carcinogenic 
phenotypes and cancer subtypes (Johnson, Warmoes, Shen, & Locasale, 2015). 
 
The morphogenesis diversity of cancer and the multistep transformation of normal cells to a 
neoplastic state are accompanied by eleven main hallmarks including, sustained proliferative 
state by reducing their dependence on exogenously derived signals in the normal tissue 
microenvironment, evading growth suppressors, resisting cell death, enabling replicative 
immortality inducing angiogenesis, activating invasion and metastasis, genome instability and 
mutation, inflammation, metabolic alterations evading immune destruction, tumors exhibit 
another dimension of complexity and deregulating cellular energetics (Hanahan & Weinberg, 
2000, 2011). 
 
Genetic alterations are mutations that occur in the gene sequence.  These alterations might 
come in the form of deletions, insertions, or substitutions. these alterations might also affect 
chromosomes, resulting in either numerical or structural changes that include insertions, 
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deletions, inversion or translocation.  While epigenetic alterations, are any change in gene 
expression that occur without altering the primary DNA sequence. like DNA methylation or 
histone modifications including; methylation, ubiquitination, phosphorylation, acetylation and 
sumolyation. All these cause adjusting gene expression profiles by chromatin –modifying 
enzymes that affect the binding pattern of transcription factors that will result in altering the 
expression pattern of other cancer cell genes (Jones & Baylin, 2007; Polak et al., 2015).  
 
1.2. Breast cancer 
 
Breast cancer is the most common cancer in women and a leading cause of cancer-related 
female deaths worldwide (Yue et al., 2017), Breast cancer, like other types of cancer is, a very  
heterogeneous cancer, with several molecular subtypes having variable profiles, which leads 
to difficulty in diagnosis and treatment (Banerji et al., 2012). Gene expression profile 
represents the most fundamental biological change that gives the apparent phenotype of 
cancer. Different gene expression regulatory levels that were studied in breast cancer and other 
cancer types (Curtis et al., 2012). However, the most critical level in the regulation of gene 
expression is the intermediate level, which include transcription (Yeh, Toniolo, & Frank, 
2013).     
 
1.3. Transcription 
  
The most important process involved in gene expression regulation (T. I. Lee & Young, 2000) 
Transcriptional regulation in eukaryotic cells is very organized and complex. It involves a 
network of transcriptional factors, chromatin organization and chromatin-modifying enzymes, 
which reflects the genomic interaction with environment (Cox & Goding, 1991). During 
cancer initiation and progression, many genes become silent or active, which alter the 
expression of several proteins including transcription factors such as MYC and p53, co-
factors, as well as histones and DNA modifying enzymes (Dawson, Kouzarides, & Huntly, 
2012). 
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1.4.  Transcription regulation  
 
 
Figure  1.1 Graphical representation of the four transcription regulatory:  
(I) Accessibility, (II) Binding, (III) Enhancer-promoter association, (IV) Genome 
high order organization (Salah et al, unpublished data) 
 
1.4.1. Chromatin accessibility  
 
Specific DNA sequence provides initial accessibility of DNA elements within active 
chromatin that permits TF binding. Moreover, accessibility to chromatin is also determined by 
modifications that takes place on histones or DNA itself. Histones are proteins on which DNA 
is wrapped to form the first level of chromatin organization; the nucleosome. In chromatin, 
there are different types of histones (H2A, H2B, H3 and H4). Different chemical 
modifications that take place on different amino acids results in differential chromatin 
accessibility (Karlic, Chung, Lasserre, Vlahovicek, & Vingron, 2010; Schneider & 
Grosschedl, 2007). For example, histone acetylation causes more accessible chromatin (Karlic 
et al., 2010). On the DNA level, methylation that takes place on CpG islands, makes the 
chromatin less accessible to TF, while methylation makes chromatin more accessible to these 
factors   (Vinarskaja, Schulz, Ingenwerth, Hader, & Arsov, 2013). 
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1.4.2. Binding of transcription complex   
 
Transcription initiation starts by binding of specific proteins, named general transcription 
factors, to the promoter or enhancer sequences of which target genes within the accessible 
chromatin, which leads to the assembly of pre-initiation complex with RNA polymerase to 
activate transcription. 
 
The regulation of TF function tack placed on different levels including TF synthesis, 
modification and localization. which, TF levels can differ under different cellular 
physiological conditions. On the TF localization level, it is well documented that the function 
of different transcription factors is dependent on post translational modifications including 
phosphorylation, ubiquitination, sumoylation, etc. where, phosphorylation of some TFs leads 
to their cytoplasmic sequestration, or nuclear translocation (Guertin & Lis, 2013). 
        
1.4.3. Enhancer-Promoter association  
 
Enhancers are a specific segments of DNA, which are located few hundreds up to mega bases 
upstream from the promoter region of target gene.  Enhancers can regulate transcription by 
creating a loop with the promoter after binding to specific TFs called the activators that can be 
closed by an insulator. Enhancers activity is regulated by histone modifications that affect the 
binding of TFs (Bulger & Groudine, 2011).  For example, in the embryonic stem cells,  master 
transcription factors, including Oct4 and Sox2 bind to an enhancer with a mediator to activate 
specific embryonic stem cell gene expression (Whyte et al., 2013).  
 
1.4.4. Genome high order organization 
 
The genome is organized into high-order complex structures by hierarchical DNA folding, 
which raises chromatin fibers, chromosome domains, and eventually chromosomes. The high-
order organization of the genome significantly affects gene regulation and the control of gene 
expression program. The chromosomal regions can be dramatically repositioned. localizing 
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activated genes on the chromosome to be concentrated along the peripheral regions. while 
inactivated genes are located in the interior of the chromosomal territories (Schneider & 
Grosschedl, 2007).  For example, it has been shown that in quiescent cells HOXB gene cluster 
is inactive because it is hidden in the interior regions of chromosome 17. Upon differentiation, 
the chromosomal territory that harbors this gene cluster is relocalized, an event that results in 
the active expression of this cluster (Chambeyron & Bickmore, 2004). 
 
HRAS 
 
Harvey Rat Sarcoma (HRAS) is a member of the RAS family that also contains NRAS and 
KRAS. It is classified as a small G protein. It has intrinsic GTPases activity, and plays 
important roles in cell growth, differentiation, and survival through the activation of different 
downstream signaling cascades (X. Chen et al., 2009; Fernandez-Medarde & Santos, 2011). 
 
RAS activation is initiated by receptor Tyrosine kinases. These receptors have two subunits 
that have the ability to phosphorylate each other. When ligand binds to the extracellular 
domain of a tyrosine kinase receptor, the two subunits of receptor dimerise and get activated 
after phosphorylation. This activation is responsible for the binding of growth factor receptor-
bound protein 2 (GRB2) protein to the cytosolic domain of the receptor tyrosine kinase. 
Afterwards, son of sevenless (SOS) protein binds to the GRB2.  Followed by RAS binding to 
the complex, and its GDP is displaced by GTP in the presence of Guanine nucleotide 
exchange factor (GEF). This reaction transforms RAS to “on” state. When the initial signal 
disappears, the GTPase activity will hydrolyze the GTP to GDP and convert RAS to the “off” 
state as described in Fig 1.2 (Margolis & Skolnik, 1994). 
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Figure  1.2 regulation of HRAS (a GTPase) activity.  
   
Activation of RAS proteins subsequently stimulate different effector proteins that activate 
several signaling cascades within the cell. The three important downstream RAS pathway 
signaling cascades are described in Fig 1.3   
 
Figure  1.3 HRAS downstream cascade pathways (Weinberg, 2007). 
 
 
Some mutations in the RAS gene prevent the GTPase to hydrolize GTP to GDP and therefore 
stabilizes RAS in the “on” state, converting HRAS to a constitutively active form. This event 
is one of the most common mutations associated with many types of human cancers. It is  
estimated that  30% of human tumors harbor a somatic mutation in RAS subfamily (Prior, 
Lewis, & Mattos, 2012). The most common mutations  that lead to “on” state of RAS are  
substitution mutations in codons 12,13,61 and 146 of the RAS gene (Fernandez-Medarde & 
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Santos, 2011). Many studies have shown the capability of mutant RAS to transform normal 
cells to cancer cells both in vitro and in vivo systems. In one study, it was shown that the co-
expression of HRAS G12V with LBX1 in MCF10A leads to various changes in these normal 
cell physiology. In this breast tumorigenesis model, the morphology of LBX1 + G12V HRAS 
infected cells were transformed to prominent elongated spindle-shaped cells. Analysis of 
mesenchymal and epithelial cell markers in these transformed cells showed a cooperative 
effect of LBX1 and G12V HRAS in inducing characteristic features of EMT. Furthermore, the 
ability of these two proteins to cooperate in generating tumors following subcutaneous 
inoculation into nude mice was tested and the results demonstrated that while MCF-10A cells 
expressing LBX1 or G12V HRAS alone developed tumors after 3 months, cells expressing 
LBX1 + G12V HRAS developed tumors within 1 month.  In another study, it was shown that, 
when HRAS was co-expressed with the anti-apoptotic gene Bim-1 (B cell-specific Moloney 
murine leukemia virus integration site 1) and cells were injected into mammary fat pad of 
female mice, cells showed accelerated tumor development (have big tumor in 1 month), 
compared to cells over expressing either HRAS or Bmi-1 alone (Datta et al., 2007). 
 
P53 
 
The p53 is a tumor suppressor protein that belongs to a larger family which also includes p63 
and p73. the p53 gene is located on the short arm of chromosome 17 in position 13.1. and the 
p53 protein consists of 393 amino acids with four functional domains. The first domain is the 
transactivation domain (TAD). Subdivided into two subdomains, AD1 (residues 1-42) and 
AD2 (residues 43-63). The N-terminal domain can interact with many regulatory proteins such 
as the negative regulatory protein MDM2 that controls p53 levels, acetyltransferases p300 and 
CBP which act as co-activators to p53-mediated transcription, and stabilization of the p53-
DNA C-terminus complex (C. W. Lee, Martinez-Yamout, Dyson, & Wright, 2010). The other 
domains, the core DNA-binding domains (DBD) (residues 94-292), which consists of two 
decameric half sites as a dimer, and contains the sequence 5′ – Pu Pu Pu C (A/T) | (T/A) G Py 
Py Py – 3′ (where Pu indicates a purine and Py indicates a pyrimidine) separated by 0 to 13 
base pairs  (el-Deiry, Kern, Pietenpol, Kinzler, & Vogelstein, 1992; Funk, Pak, Karas, Wright, 
& Shay, 1992). The two half sites form a tetramer in the oligomerization domain (residues 
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317- 353) (Ho, Fitzgerald, & Marmorstein, 2006), which confers flexible link with DNA-
binding domain to give p53 the accessibility  to bind with different DNA sequences resulting 
in transcriptional activation or repression for wide range of genes (Y. Chen, Dey, & Chen, 
2010; Malecka, Ho, & Marmorstein, 2009). Finally, the C-terminus domain (CTD) (residues 
353-393), acts as a negative or positive regulator for sequence-specific DNA binding domain. 
For example, p53 C-terminus domain binds with chromatin to access p21 promoter (Espinosa 
& Emerson, 2001; Fischbach et al., 2017).  
 
Tp53 plays a critical role in modulating the expression of genes involved in cell cycle arrest 
and apoptosis. In stress conditions caused by DNA damage like UV, chemicals or viruses, or 
hypoxia, Tp53 stabilization leads to transcriptional modulating for different Tp53-response 
genes, which produce proteins that regulate a large number of signal transduction pathways 
and a number of auto regulatory feedback loops in the presence of p53 effect. One of the p53 
target genes is p21 which is a potent cyclin-dependent kinase inhibitor that causes cell cycle 
arrest. It is an important regulator of cell cycle transition from G1 to S phase (Tang et al., 
1998), Other p53 target genes include BCL2 associated X (BAX) that acts as an accelerator for 
apoptosis (Miyashita & Reed, 1995), and Mouse double minute 2 (MDM2). Transcription of 
MDM2 can be induced by binding of p53 or RAF to its promoters region (Ries et al., 2000). 
MDM2 is a major negative regulatory protein of p53, it binds to p53 and transfers it to the 
cytoplasm for degradation (Iwakuma & Lozano, 2003). A new chemical that was discovered 
recently, Nutlin-3a is used to increase the stability of p53 through binding to MDM2 (B. 
Wang, Fang, Zhao, Xiang, & Wang, 2012). p53 dysfunction or inactivation due to DNA 
mutations, is an important driver for carcinogenesis. Studies showed that p53 is mutated in 
more than 50% of human cancers (Espinosa & Emerson, 2001). Other studies showed that, the 
activation of the oncogene HRAS G12V and inactivation of the tumor suppressor p53 gene are 
strongly associated with cancer transformation (Solomon, Brosh, Buganim, & Rotter, 2010). 
In an In vivo study on HRAS activation and p53 inhibition, this combination activates EMT 
and increases stemness in urothelial progenitor cells (He, Melamed, Tang, Huang, & Wu, 
2015). In another study, it was suggested that there is a cross talk between p53 and activated 
HRAS G12V. In this study, it was demonstrated that the B-cell translocation gene 2 (BTG2) 
binds to HRAS G12V and represses its activity by reducing its GTP loading state, which in 
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turn causes a reduction in cancer-related gene signature (CGS) expression. In addition, 
activating transcription factor 3  (ATF3) binds directly to the CGS promoters following p53 
stabilization and represses their expression.(Buganim et al., 2010).   
 
p63 
 
This is a member of the p53 family located on the long arm of chromosome 3 at position 28.  
The protein is encoded by alternative promoters to yield two main isoforms. These isoforms 
either contain an N-terminal p53-homologous transactivation domain (TAp63) or lack this 
domain (ΔNp63)(Yang et al., 1998). Both TA and ΔN transcripts are alternatively spliced at 
the 3′ end to generate different C-terminal isoforms, called α, β and γ (Di Como et al., 2002; 
Ghioni et al., 2002), as explained in Fig 1.4.. 
 
Figure  1.4 Human p63 isoforms. Exon schema and corresponding domains of the human Tp63 gene. 
Alternative promoter usage produces TA (transactivation) and N-terminally truncated (ΔN) isoforms, and 
alternative splicing produces C-terminal variants (Melino, 2011)  
 
p63 has transactivation domain, DNA binding domain, and an oligomerization domain similar 
to that of p53, but are different in the C-terminal domain. The similarity in the domains 
produces redundancy in p53 and TAp63, which function in cell cycle arrest and cell death 
induction. The ΔNp63, has a critical role in cellular differentiation and epithelial development. 
Both isoforms act as inhibitors of cancer progression  (Bergholz & Xiao, 2012; Jung, Qian, 
Yan, & Chen, 2013).  
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In our work, lentiviral particles a cellular transformation model by creating stable MCF10A 
clones that overexpress the oncogene HRAS was generated using lentiviral vectors. To 
confirm transformation, we tested different cancer cell hallmarks. Using this transformation 
model, we were able to identify important transcriptional reprogramming that involved many 
genes including p53 and p63.  In order to evaluate the role of these transcription factors in cell 
transformation, we reactivated the functions of these genes in our cell model and tested for the 
same cancer hallmarks that we tested before. Our results, showed that the reactivation of p53 
and p63 was enough to revert to certain extent some the transformation process-related 
phenotypes.   
 
 
 
 
1.5. Problem Statement and motivation of study 
 
Cancer is a genetic disease. Mutations and epigenetic alterations result in altered specific gene 
expression programs as well as misregulation of cellular signaling and 
communication (Hanahan & Weinberg, 2011). While pathogenic genetic changes frequently 
affect the activities of oncogenes and desregulate tumor suppressor genes, epimutations mostly 
affect TF binding and as such gene regulatory modules. In conjunction, these events abrogate 
cellular homeostasis, resulting in transformation and ultimately tumor formation and 
metastasis (Northcott et al., 2014). Current efforts to characterize the pathways contributing to 
breast cancer development mostly focus on either the identification of upstream 
mutations (Cancer Genome Atlas, 2012) or downstream RNA and protein expression patterns 
of cancer cells (Curtis et al., 2012). However, demarcating the intermediate molecular events 
that trigger gene expression programs and holds great promise for generating novel and 
improved diagnostic tools and identifying relevant targets for therapeutic interventions (Yeh et 
al., 2013). This is especially invaluable for aggressive subtypes such as triple-negative/basal-
like breast cancer which poses a major challenge in the clinic due to the current lack of 
effective targeted therapies (Mayer, Abramson, Lehmann, & Pietenpol, 2014). 
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This work is part of a comprehensive project that aims to find common transcriptional 
reprograming events that results from cancerous transformation. Here, we aimed to test our 
ability to generate an in vitro transformation model and use it in our research. The model can 
potentially be used to validate our findings from transcription regulation studies (Fig. 1.5).    
 
 
Figure  1.5 Our working model. Generation of a cellular model, its validation and evaluation of the role of 
specific TF in the transformation process. (Salah et al, unpublished data)    
 
1.6. Hypothesis  
 
Our current project is based on our hypothesis that cancer cell transformation that results from 
various molecular mechanisms must involve common transcriptional reprogramming events 
that can be used as biomarkers for early detection or as targets for therapy. Our preliminary 
data suggest that both p53 and p63 functions are lost in transformed cells. Thus our hypothesis 
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the loss of function of these genes is important for cell transformation and that the re-
expression would at least partially reverses this transformed phenotype.   
 
1.7. Objective of study 
  
1.7.1. To generate an in vitro transformation model for breast cancer using a known HRAS        
mutation. 
1.7.2. Validation of the system utility to reverse the transformation phenotype using TFs       
known to be involved in the transformation process.  
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Chapter 2 
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
2.    Methodology 
2.1.     Materials 
 
Table  2.1-A: list of material used in methodology 
 
No Material Manufacture 
1 MDEM/F12 media Biological industries 
2 RPMI (1640) media Gibco Thermofisher 
3 Horse serum Biological industry 
4 Fetal bovine serum Gibco Thermofisher 
5 Hydrocortisone Sigma 
6 Insulin Sigma  
7 Epidermal growth factor (EGF) Sigma 
8 Cholera toxin Sigma 
9 Glutamine Biological industries 
10 Penicillin/streptomycin  Biological industries 
11 Dimethyl sulfoxide Sigma 
12 Sterile phosphate buffer saline PBS   Biological industries 
13 PWZL-hygro HRAS  Addgene  
14 PWZL-hygro EV Addgene 
15 NOPLX305-TP63-HA-LRES-PURO-K4 Gift from Prof.Stefan Wiemann  
16 GAG-pol plasmid Addgene 
17 VSV-G plasmid  Addgene  
18 Mirus TransLTi Mirus Bio  
19 Ampicillin Sigma 
20 Puromycin Sigma 
21 Maxi prep kit Qaigen  
22 Mini prep kit Qaigen  
23 Q5® Site-Directed Mutagenesis Kit BioLabs 
24 XTT kite Biological industries 
25 Trypane blue  Biological industries 
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Table  2.1-B: list of material used in methodology 
 
2.2.Equipment and tools 
 
Table  2.2:list of Equipment and tools used in methodology 
No Equipment or tool Company Industrial 
country  
1 Inverted microscope Olympus ck40-SLP Japan 
2 Biological hood (HERA guard) Heraeus Germany 
3 Biofuge Stratos Reconditioned 
 
Heraeus 75005289R Germany 
4 Biofuge Fresco Heraeus 75005521 Germany 
5 Hera cell 150 CO2 Incubator Heraeus Germany 
6 Labofuge 200 centrifuge  Heraeus Germany 
7 Autovortex SA6 Stuart Scientific U.K 
8 Water Bath Orbital Shaking Grant OLS200 U.K 
9 Water Bath Grant LTD6G U.K 
10 Ultracentrifuge  BECKMAN COULTER optima 
LE80H 
U.S.A 
11 SPIN-micropipette site Nano Spinreact china 
12 Digital dry bath  Labnet U.S.A 
13 Elisa reader BioTek EL-X800 U.S.A 
14 Analytical Balance METLER TOLEDO AB104 Switzerland 
15 Autoclave  HIRAYAMA HV-110 U.S.A 
16 RT-PCR (Applied Bio-systems 7500 FAST 
Real Time PCR 
Singafora 
17 PCR machine 96 well  Applied Biosystem #9902  Singapore  
No Material Manufacture 
26 Isopropanol biological gradient Sigma 
27 Ethanol biological gradient Sigma 
28 Chloroform biological gradient Sigma 
29 qScript™cDNA synthesis kit Quanta Biosciences 
30 SYBR® Green Applied Biosystems 
31 TRIZOL Sigma 
32 Nutlin-3a Sigma 
33 Polyvinylpyrrolidone-free polycarbonate filters Costar Scientific 
34 Diff-Quick System  Dade Behring 
35 2-Hydroxyethyl Agarose Sigma 
36 MCF10A KO p53 Gift from Prof.Stefan Wiemann 
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2.3. Methods 
 
2.3.1. Cell culture  
 
2.3.1.1. Media preparation 
 
MCF10A cells were grown in DMEM/F12 supplemented with 5% horse serum, 20 
ng/mL EGF, 10 mg/mL insulin, 0.5 mg/mL hydrocortisone, 100 ng/mL cholera 
toxin, 1% glutamine and 1% Penicillin/Streptomycin.  
 
HEK293T cells were grown in RPMI (1640) supplemented with 10% fetal bovine 
serum, 1% glutamine and 1% Penicillin/Streptomycin. 
 
Freezing media was prepared to contain 70% growth media, 20% fetal bovine 
serum and 10% DMSO. 
 
2.3.1.2. Cell passage 
 
To pass cells, old culture media was aspirated and cells were washed with 0.5 ml 
PBS X1. Afterwards, PBS was removed, and 1.0 ml trypsin was added. Then, part 
of trypsin was removed and incubated in CO2 incubator at 37 0C until the cells 
detached from the plate. Finally, cells were mixed with the media and certain 
amount of cells was passed, depending on the experiment needs, and incubated in 
CO2 incubator at 37 0C. 
 
2.3.1.3. Freezing cells 
 
Cells were washed and trypsinized as mentioned above. When ready, cells were 
collected in freezing media that contain 70% growth media, 20% fetal bovine 
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serum and 10% DMSO. and transferred to cyrotubes, gradually frozen and finally 
stored in liquid nitrogen.  
 
2.3.1.4. Cell thawing  
 
To restore cells from liquid nitrogen storage, cryotubes containing the cells were 
immediately transferred from the liquid nitrogen tank to a 37 0C water path. After 
thawing, cells were transferred to a new conical tube containing 5 ml fresh 
medium. Afterwards, cells were resuspended in fresh media and plated.  
 
2.3.2. Preparation of competent bacteria (DH5α) 
 
To prepare chemically competent bacterial cells, one DH5α colony was grown in   250 
ml LB media until the OD for a 1/5 dilution at 600 nm is between 0.04- 0.08. Cells were 
centrifuged at 4000 RPM for 10 min and the cell pellet was re-suspended in 50 ml of 0.1 
M CaCl2 and incubated on ice for 15 min. After that, cells were centrifuged for 10 min at 
4000 RPM at 4 0C.  Finally, the pellet was resuspended in 10 ml of 0.1 M CaCl2 
containing 350 µl DMSO, split into Cryotubes, and immediately frozen in liquid 
nitrogen.   
 
2.3.3. Bacterial transformation using heat shock 
 
Competent bacteria (DH5α) tube was taken from liquid nitrogen and directly incubated 
on ice for 15-30 min, then 50 µl of DH5α was put in cold Eppendorf tube. Then 2-10 ng 
of plasmid was added to the tube. After that the tube was incubated on ice for 30 min. 
After incubation the tube was quickly transferred and incubated at 42 0C in water bath 
for 1min. Then the tube was returned to ice for 5 min. Finally, the bacteria (DH5α) was 
grown in LB agar plate with selection antibiotic for the plasmid and was cultured in 
incubator at 37 0C for 24 h. 
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2.3.4. Lentivirus preparation  
 
Lentivirus particles were prepared by a three-plasmid expression system, in which 293T 
cells were cotransfected with the following three vectors: packaging (CMVΔR8.91), 
envelope (CMV-VSV-G), and transfer vector. One day before transfection, 293T cells 
were plated to 60% confluency. The next day, cells were fed with fresh medium and 
transfected with the three plasmids using transfection reagent (Mirus TransLTi). 
Medium was changed 24 h after transfection. On days 2 and 3 after transfection, 
medium was collected to recover excess viral particles. The collected medium was 
filtered and kept at -80 °C. 
 
2.3.5. Infection and selection 
 
To prepare cell clones harboring the gene of interest, lentivirus particles were added to 
cells and incubated with them for 48 h in CO2 incubator at 37 0C. After two days, the 
infection media was changed with fresh media containing the appropriate selection 
antibiotic. The selection process was continued until complete death of control cells that 
were not infected. Control cells for HRAS and p63 clones were cells infected with 
empty vector (EV) of the viral vector backbone (pwzl-hygro for HRAS and NOPLX305 
-HA-LRES-PURO-K4 for p63).   
 
2.3.6. Primer design 
 
Primer 3 software was used (http://primer3.ut.ee/) for Primers design and used in our 
research as listed in table 2.3. 
 
 
 
 
 
18 
 
 
            Table 2. 1: list of our primers. 
 
No gene AN Primer  AT 
1 HRAS NM_001130442.2 F.P 5’- tgccatcaacaacaccaagt-3’ 
R.P 5’- agccaggtcacacttgttcc-3’ 
53 0C 
2 p21 NM_001291549.1 F.P 5’- cgtcaaatcctccccttcct-3’ 
R.P 5’- atgggttctgacggacatcc -3’ 
50 0C  
3 BAX NM_001291428.1 F.P 5’- ggttgtcgcccttttctact-3’ 
R.P 5’-aagtccaatgtccagcccat -3’ 
54 0C 
4 p63 NM_003722.4 
 
F.P 5’- acaggaagacagagtgtgct-3’ 
F.P 5’- catccctccaacacaactgc-3’ 
53 0C 
5 HUBC NM_021009.6 F.P 5’- gtcgcagttcttgtttgtgg-3’ 
R.P 5’-gatggtgtcactgggctcaa-3’ 
53 0C 
 
2.3.7. Site direct mutagenesis  
 
To generate G12V mutant plasmid, we did site directed mutagenesis of the wt HRAS in 
the PWZL-hygro HRAS plasmid using QuikChange XL Site-Directed Mutagenesis Kit 
from Agilent, according to manufacturer instructions. Afterwards, the reaction product 
was used to transform DH5α cells. Then this transformation reaction was cultured on LB 
plates containing ampicillin as a selection marker for successful transformation. To 
search for successful mutant palsmids, 10% of growing colonies were grown in 5ml 
liquid LB media containing ampicillin. From these cultures plasmid was prepared using 
NucleoSpin kit, according to manufacturer instructions. These plasmids were then sent 
for Sanger sequencing to ensure mutagenesis of the specific site.     
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2.3.8. Plasmids extraction by Maxiprep  
 
After transforming the bacteria with the needed plasmid, one colony of transformed 
bacteria was grown in 250 ml liquid LB containing the selection antibiotic and grown at 
37 0C for 16-18 h.  later, bacteria collected and plasmid was prepared using Maxiprep 
Kit from Invitrogen according to manufacturer instruction. 
 
2.3.9. Cell count 
 
 3x104 cells were seeded in 6 well plate in triplicates, after 1 day of incubation (D0) the 
culture media and the adherent cells were collected in 15 ml tubes.  The growth media 
was collected to count floating cells, while adhering cells were collected to assess for 
differences in cell count. After centrifugation at 1200 RPM for 10 min, the supernatant 
was removed and cells were resuspended in a specific volume of media. After complete 
resuspension of cells, we put 10 µl of the homogenous supernatant in champers slide and 
counted the cells. 
   
2.3.10. XTT test 
 
2 X103 cells were seeded triplicate in 96 well plate. for 24, 48, and 72 h later, cell 
proliferation was measured for 3 days using the XTT test, according to the 
manufacture’s instructions. 
 
2.3.11. Wound healing assay 
 
25x104 cells/well were seeded in 12 well plate wells to form a 100% confluent layer. 
One day after the layer was wounded using the 10μl pipet tip and monitored for wound 
healing at 0 h and 24h in minimal growth factor medium. 
 
2.3.12. Survival assay 
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200 and 400 cells were seeded in triplicates in 6 well plate. The media was changed 
every 3-4 days until colonies were visible to the naked eye. Then the media was 
removed and wells were washed with PBS X1, aspirated and wells were left to dry. 
After drying, cells were fixed using absolute methanol for about 15 min. Afterwards, 
wells were left to dry and then stained using Coomassie blue. Finally, the stain was 
removed and wells were washed using tap water.   
 
2.3.13. Matrigel invasion assay 
 
Blind well chemotaxis chambers with 13-mm-diameter filters were used for this assay. 
Polyvinylpyrrolidone-free polycarbonate filters, 8-mm pore size, were coated with 
basement membrane Matrigel (25 µg/filter). Briefly, the Matrigel was diluted to the 
desired final concentration with cold distilled water, applied to the filters, and dried 
under a hood. Cells (2 × 105 to 3 × 105), were suspended in DMEM containing 0.1% 
bovine serum albumin (BSA), were added to the upper chamber. Conditioned medium 
of 3T3 fibroblasts was applied as a chemoattractant and placed in the lower 
compartment of the Boyden chamber with the addition of EGF (20ng/ml). Assays were 
carried out at 37 °C in 5% CO2. More than 90% of the cells attached to the filter after 
incubation overnight. At the end of the incubation, the cells on the upper surface of the 
filter were removed by wiping with a cotton swab. The filters were fixed and stained 
with Diff-Quick System. Cells from various areas of the lower surface were counted and 
each assay was done in triplicate. 
 
2.3.14. Soft agar assay 
 
The assay media is composed of an upper and a lower layer. lower layer (2 ml) is 
composed of MCF10A media containing 0.6% 2-Hydroxyethyl Agarose. After pouring 
the lower media in 6 well plates, the plates were incubated at 4 0C for 1 h. Then 2x104 
cells were seeded at the upper layers (1.2 ml) for each well. The upper media contained 
21 
 
MCF10A media with 0.3% 2-Hydroxyethyl Agarose. After adding the upper layer, 
plates were   incubated in CO2 incubator until the point where colonies were able to be 
seen by naked eye. The top layer was changed every 3-4 days.  
 
2.3.15. 3D culture assay 
 
Matrigel was incubated on ice overnight, then 3000 cells were seeded on a solidified 
layer of growth factor reduced Matrigel measuring approximately 1–2 mm in thickness. 
The cells were grown in an assay medium containing 5 ng/ml EGF and 2% Matrigel 
then incubated in CO2 incubator at 37 0C. 
 
2.3.16. RNA Extraction 
 
90x104 cells were seeded in 10 cm plate. After 24 h of incubation the old media was 
removed and the plate was incubated on ice for 1min. Then 1 ml Trizol reagent was put 
to each plate and incubated on ice with shacked for 5 min. After that the plate was 
washed well with Trizol reagent and collected in RNase free tube with incubation on ice. 
Then 200 µl chloroform was added to each tube with shacked well and incubated on ice 
for 15 min. After incubation the tube was centrifuged at 12000 RPM for 15 min on 4 0C. 
After centrifugation the first supernatant layer was transferred to RNase free tube and 
500 µl cold isopropanol was added with mixed well then incubated in ice for 15 min. 
After incubation we centrifuged on 4 0C at 12000 RPM for 15 min. After that we 
decanted the supernatant and put 500 µl 70% Ethyl alcohol. Then we centrifuged on 4 
0C at 12000 RPM for 10 min. After centrifugation we decanted the supernatant and dry 
the pellet for 1 min. Then resuspended the pellet in ultra-pure water and incubated in 
dray bath at 60 0C for 5 min. Finally, we checked the RNA by measured the 
concentration and run on gel electrophoresis.     
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2.3.17. cDNA synthesis 
 
1 µg of RNA samples were used to synthesis cDNA, mixed with 4 µl RT buffer, and 1µl 
enzyme in a PCR tube and completed the volume to 20 µl by added ultra-pure water. 
Then was transferred the tube to PCR machine to synthesis cDNA at specific program 
according to manufactures instructions. 
 
2.3.18. RT-PCR  
 
1 µl of primer (10 µM), 3 µl of cDNA 1 µg/µl (1:10) was diluted, 6 µl ultra-pure water 
and 10 µl SYBR® Green were put in each well of 96 well RT-PCR plate. Then the seal 
was put on the RT-PCR plate and the plate was centrifuged for 5 min. Finally, the plate 
was put in RT-PCR machine, and was worked in the program of table  
         Table 2.4: RT-PCR program for SYBR® Green mix  
Pre-conditioning activation Denaturation Anneal/Extend 
50 0C/2 min 95 0C/10 min 95 0C/15 sec 60 0C/1 min 
  40 cycles 
 
2.3.19. polyhema Coating and Anoikis assay 
 
Polyhema was prepared by dissolving 12 g in 1 L of 95% ethanol, and incubated at 60 
0C overnight, finally the mixture was filtered by 0.2 µm filter. Then, enough amount was 
put in the plate to coat the plate surface, and was left overnight in the hood until 
completely evaporated, then the plate was stored at 4 0C until use. To assess for cell 
death through Anoikis, we plated 50X103 cells in 12 well plate wells coated with 
Polyhema. 4 days later, cells were collected from the wells and counted manually using 
Trypan blue exclusion assay to differentiate between dead and living cells. 
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Chapter 3 
ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
3. Results and discussion 
 
3.1.  Generation of HRAS G12V  
 
To generate hot spot mutation from wt HRAS, we used site directed mutagenesis to covert 
codon 12 of the HRAS gene from glycine to valine in pwzl-hygro HRAS plasmid. 
Sequencing results showed that we had successfully converted wt to V12 as shown in Fig 
3.1.      
   
  
A                                                                                  B  
 
Figure 3. 1 Alignment between pwzl-hygro HRAS plasmid and HRAS gene sequence by BLAST 
tool. Sequencing results where (A) HRAS Wt and (B) HRAS G12V.    
 
3.2.  Validation of HRAS overexpression in HRAS clones.  
 
Our first aim in this project was to create a transformed cellular model harboring known 
HRAS mutation (G12V). To generate HRAS MCF10A clone of cells overexpressing HRAS, 
we infected MCF10A cells with either lentiviral vectors either harboring HRAS or just the 
empty viral vector (EV, to be used as control). 48 h post infection, we did clone selection 
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using the selection marker (antibiotic resistant gene) present in the viral vector backbone 
(pwzl-hygro plasmid). Selection was completed after 3-4 days using100 µg/ ml hygromycin. 
To validate HRAS overexpression in our HRAS clones, we did RT-PCR using HRAS specific 
primer (table 2.3). As shown in Figure 3.2 our HRAS clone expressed about 7 folds HRAS 
mRNA relative to control (EV) cells. 
  
Figure  3.2 Expression level of HRAS in MCF10A clones. Real time PCR results 
on mRNA extracted from the cells indicated in the graph. Error bars represent the 
standard error of the mean of three experiments done in triplicates. to defined the 
significances different between MCF10A and MCF10A HRAS cells by T-test to 
calculate p-value. (** means that p-value>0.05 and * means that p-value <0.05), to 
a significant results the p-value <0.05. 
 
 
3.3. Phenotypic changes in MCF10A cells with HRAS induction. 
 
To make sure that the transformation process was succeeded, different tumor hallmarks 
related to HRAS function were tested.  
 
3.3.1. Effect of HRAS overexpression on cell proliferation   
 
G12V is a hot spot mutation in HRAS gene that results in cancer cells in uncontrolled 
cell proliferation. To test the effect of HRAS on MCF10A cell proliferation, we used 
XTT test. As shown in Fig 3.3 HRAS clones showed higher proliferative index 
compared to control cells. 
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Figure 3. 3 HRAS increases cell proliferation of MCF10A cells. 
Representative graph showing the relative proliferation rate of HRAS 
compared to control cells using XTT assay. Cell growth was monitored 
over three days. Cell were assessed in triplicates per each time point. Y 
axis represent the relative cell proliferation index related to day zero. Bars 
represent standard error of the mean of three readings per point.  to defined 
the significances different between MCF10A and MCF10A HRAS cells by 
T-test to calculate p-value. (** means that p-value>0.05 and * means that 
p-value <0.05), to a significant results the p-value <0.05. 
       
Previous in vitro and in vivo studies showed that over expression HRAS harboring 
G12V increases proliferation in transformed cells, exactly similar to what we got in our 
experiments.  One of these studies showed that fibroblast cells (IMR90, MEF, and 
REF52) that were infected with HRAS harboring G12V, the  proliferation rate was 
accelerated compared to control cells (Serrano, Lin, McCurrach, Beach, & Lowe, 
1997). In another in vivo study, it was shown that HRAS transformed MCF10A can 
create tumor within three months after injection into mice (Datta et al., 2007). These 
studies indicate that HRAS has a role in the transformation of normal cells to cancer, 
whereas prevents the GTPase activity and allow the proliferation downstream signaling 
pathways to be on all the time. 
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3.3.2. HRAS induces higher cell survival in MCF10A cells  
 
Throughout tumorigenesis, cancer cells acquire the capacity of being autonomous, ie. 
independent of external signals to grow and survive. In order to check for this capacity 
in the HRAS clones, cell survival assay was used. Here, cultured cells with a very low 
number of cells in cell culture plates to prevent cell-cell communication. As shown in 
Fig 3.4, mutant HRAS clones have a higher survival index in comparison to control 
cells. Of note HRAS clone colonies were larger in diameter that of control cells 
indicating also a higher proliferative rate in these cells. 
 
Figure 3. 4 HRAS transformed MCF10A clones have more survival index. 
Representative statistical analysis of the survival rate of HRAS transformed 
cells measured using cell survival assay. Experiments were done in triplicates 
and the bars represent the standard error of the mean. to defined the 
significances different between MCF10A and MCF10A HRAS cells by T-test 
to calculate p-value. (** means that p-value>0.05 and * means that p-value 
<0.05), to a significant results the p-value <0.05. 
        
This result is consistent with HRAS function to induce and stimulate downstream 
signaling pathways without need to extracellular signaling pathways activation. These 
results show that each cell has the ability to grow and create colony without the need 
for cell-cell interaction, a phenomenon that was connected to  HRAS transformation 
(Datta et al., 2007; Yu et al., 2009). On the molecular level, different studies have 
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shown that  HRAS induces the cell survival by activating the PI3K or the RAF-MEK-
ERK pathways,  which play a critical role in promoting cell survival and proliferation 
(McCain, 2013; Rajalingam, Schreck, Rapp, & Albert, 2007).  
 
3.3.3. HRAS overexpression in MCF10A induces cell tumorigenicity in vitro 
 
One of the phenotypes that cancer cells acquire during transformation process is their 
ability to grow and survive independent of the extracellular matrix (in suspension). To 
that in the MCF10A transformed cells, we did soft agar assay (one of the most popular 
techniques used to test for transformation). Was done as expected, HRAS 
overexpression in MCF10A lead to the formation of many colonies in soft agar 
compared to non-transformed control cells (Fig 3.5).    
 
Figure 3. 5 HRAS transforming in MCF10A clones have more ability 
to create colonies. the figure show the number of colony created in agar 
layer. Experiments were done in triplicates and the bars represent the 
standard error of the mean to defined the significances different between 
MCF10A and MCF10A HRAS cells by T-test to calculate p-value. (** 
means that p-value>0.05 and * means that p-value <0.05), to a significant 
results the p-value <0.05. 
 
Similar to our results, different previous studies have shown that overexpression of  
HRAS lead to tumorigenesis in vitro (Datta et al., 2007). In one study, it was shown 
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that primary human mammary epithelial cell transformation with  HRAS and co-
expression of SV40 large-T antigen and hTERT genes  increased tumorigenesis as 
measured by soft agar assay (Elenbaas et al., 2001).  
 
3.3.4. HRAS transformation of MCF10A cells lead to Anoikis resistance 
 
Anoikis is a form of programmed cell death (apoptosis) that results from growing 
adherent cells in suspension. In cancer, resistance to this type of cell death is extremely 
important for cancer cells to survive in the blood stream during invasion and  
metastasis, which is a cancer hallmark (Hanahan & Weinberg, 2011). To elucidate 
whether HRAS overexpression leads to gaining this important cancer hallmark, cells 
were depleted from their interaction with the extracellular matrix (ECM) by culturing 
them on plates coated with polyhema. To differentiate between dead and living cells, 
we used Trypan blue exclusion assay. Upon calculating the percentage of dead cells, 
we noticed that around 80% of control cells died after growing for 48 in suspension, 
while only around 30% of HRAS cells died over the same period of time (Fig 3.5).   
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Figure 3. 6 Anchorage independent cell growth of HRAS MCF10A 
clones. The figure shows the percentage of dead cells cultured on polyhema 
coated plates. different between MCF10A and MCF10A HRAS cells by T-
test to calculate p-value. (** means that p-value>0.05 and * means that p-
value <0.05), to a significant results the p-value <0.05. 
 
 
In order to resist Anoikis, epithelial cells must loose their epithelial identity and 
become more mesenchymal. Indeed and in concordance with our findings, previous 
studies proved that HRAS is capable of transforming epithelial cells into mesenchymal 
cells that are able to resist Anoikis (Makrodouli et al., 2011; Yu et al., 2009). This 
HRAS induced phenotype was shown to be related to the activation of different 
signaling pathways including RAS–RAF–MEK–ERK and PI3K pathways. 
(Rajalingam et al., 2007).     
 
3.3.5. HRAS induces invasiveness in MCF10A cells 
 
The transformation of epithelial cells by oncogenes like HRAS leads to the acquisition 
of mesenchymal phenotype that usually has the ability to migrate and invade ECM. To 
test whether our clones are also more invasive, we measured their invasive potential 
using Boyden chamber Matrigel invasion assay. In comparison to non-transformed 
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control cells, HRAS clone cells invaded the Matrigel coated filter as observed in Fig 
3.7. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This result shows that HRAS overexpression in MCF10A leads to cell transformation 
from epithelial to a more mesenchymal phenotype (capable of forming colonies in soft 
agar, and more resistant to Anoikis). (Thus it was expected that these observation 
clones will be more migratory and more invasive). This, similar to many previous 
studies that have shown  HRAS increases cell invasiveness  in vitro (Datta et al., 2007) 
by inducing EMT (Makrodouli et al., 2011), Moreover, it was shown that HRAS G12V 
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Figure 3. 7 Invasive phenotypes of HRAS clones. A: Representative micrograph showing 
cells that were capable of invading Matrigel coated filters in Boyden chamber Matrigel 
invasion assay. Invading cells were fixed and stained with Diff-Quick System Kit. 
Experiments were performed in triplicates. B: quantitative representation of the data in A. 
Bar Bars represent standard error. different between MCF10A and MCF10A HRAS cells 
by T-test to calculate p-value. (** means that p-value>0.05 and * means that p-value 
<0.05), to a significant results the p-value <0.05.  
A 
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induces EMT and the invasive phenotype of MCF10A by activating  PI3K pathway 
and its downstream effector protein Rac1 (Shin, Kim, Song, Kim, & Moon, 2005). 
 
3.4. p53 stabilization in MCF10A HRAS clones using Nutlin-3a was capable of reversing 
the tumorigenic phenotype of HRAS clones. 
 
As mentioned above, one major goal of this research project is to assess how transformation 
results in transcriptional reprogramming. Upon testing the pattern of motif binding on the 
whole genome level, our results revealed that the binding motif of p53 is the most prominent 
in the regulatory loci that were lost and associated with down-regulated genes upon HRAS 
expression (Salah et al, not shown, unpublished data). To test whether induction of p53 
function would be sufficient to rescue cell phenotypes induced by HRAS transformation, 
small-molecule antagonist of MDM2 Nutlin-3a, was used to restore p53 protein function. Of 
note Nutlin-3a is known and wildly used in research to restore p53 function (Drakos et al., 
2011; Drakos et al., 2007).  
 
3.4.1. Nutlin-3a inhibits cell proliferation and induces cell death in MCF10A-HRAS 
cells.  
 
Uncontrolled cell proliferation and resistance to cell death are major phenotypes 
acquired throughout cancer transformation. As shown above, HRAS induces cell 
proliferation and decreases cell sensitivity to death.  To test whether p53 function 
induction reverses these phenotypes in HRAS transformed cells, direct cell count and 
XTT assays after inducing p53 by using Nutlin-3a were evaluated. As shown in Fig 3.8 
and 3.9, respectively, induction of p53 decreased cell proliferation and increased cell 
death.  To further prove the effect of p53 reactivation on cell proliferation, and to show 
that the effect of Nutlin-3a is mediated through p53, we used XTT proliferation assay 
on both WT and KO p53 MCF10A cells. As shown in Fig 3.10, the activation of p53 
resulted in reduced cell proliferation rate compared to untreated cells. As expected this 
effect was not observed upon using p53 KO cells, showing that Nutlin-3a effect is 
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through p53. Altogether, these results prove that HRAS mediates its effect on cell 
proliferation and cell death by inactivating p53 function. 
 
 
Figure 3. 8 Nutlin-3a reverses HRAS effect on cell proliferation. Representative graph 
showing the relative proliferation rate of HRAS with and without Nutlin-3a treatment using 
cell count assay. Cell growth was monitored over three days. Cell were assessed in 
triplicates per each time point per each Nutlin-3a concentration. Bars represent standard 
error of the mean of three readings per point.   
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Figure 3. 9 Nutlin-3a reverses HRAS effect on cell death. Representative graph showing the 
relative proliferation rate of HRAS with and without Nutlin-3a treatment using cell count assay. 
Cell growth was monitored over three days. Cell were assessed in triplicates per each time point 
per each Nutlin-3a concentration. Bars represent standard error of the mean of three readings per 
point.   
 
Figure 3. 10 Nutlin-3a reverses HRAS effect on cell proliferation through p53. 
Representative graph showing the relative proliferation rate of HRAS with and without Nutlin-3a 
treatment on WT and KO p53 cells, using cell count assay. Cell growth was monitored over three 
days. Cell were assessed in triplicates per each time point per each Nutlin-3a concentration. Bars 
represent standard error of the mean of three readings per point.   
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P53 is a tumor suppressor gene which is inactivated in many types of cancer, including 
breast cancer (Espinosa & Emerson, 2001). Thus, in addition to our not shown 
unpublished data that demonstrates that p53 regulatory sites are one of the mostly lost 
upon HRAS transformation, an expected, the reactivation of p53 in HRAS clones 
would rescue some of the tumorigenic phenotypes gained upon HRAS transformation. 
And indeed, our data here shows that p53 activation was enough to rescue some of 
HRAS oncogenic phenotypes. Moreover, it was published that Nutlin-3a was able to 
inhibit cell growth and induce apoptosis by increasing BAX and PUMA, and also leads 
to cell cycle arrest by increasing p21 expression in diffuse large B-cell lymphoma, of 
course as a result of p53 stabilization in these cells (Drakos et al., 2011).   
 
3.4.2. Nutlin-3a inhibits cell migration of both MCF10A and MCF10A-HRAS cells. 
 
One of the phenotypes that accompany cancer transformation is gaining of cell 
migratory phenotype. Above, we have shown that HRAS increase cell migration and 
invasion (Fig 3.7).  Here we wanted to test the effectiveness of Nutlin-3a on HRAS 
induced cell migration. To do so, we did cell migration assay on cells with, or without 
Nutlin-3a treatment. Of note, in this assay, Nutlin-3a was added for a short period of 
time to ensure that the effect on cell migration is not as a result of cell death because of 
Nutlin-3a treatment.  As shown in Fig 3.11. While in HRAS transformed cells were 
able to close the wound, Nutlin-3a-treated cells didn’t. These results show that HRAS 
induces this phenotype by inactivating p53 and that reactivation of p53 is enough to 
reverse this phenotype.  
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Our results like previous studies showed the capability of HRAS to confer migration 
for transformed cells (Fig 3.10). On one previous study showed that Nutlin-3a not only 
induced cell cycle arrest and apoptosis, but also decreased migration capability by 
inhibiting the RhoA and Rac1 expression in p53 wt human cancer cells, these two gene 
induce the lamellipodia formation, this formation proved the capability of cells to 
migration (Moran & Maki, 2010).    
 
3.4.3. Nutlin-3a inhibits cell survival of both MCF10A and MCF10A-HRAS cells 
 
More cancer cells resistance to variant conditions that leads to death were seen in 
HRAS transformed cells Fig 3.4. To test the effect of p53 reactivation on this 
phenotype we conducted cell survival assay on Nutlin-3a treated and untreated cells. In 
this assay, we were able to show that p53 activation is capable of reversing cell 
survival phenotype induced by HRAS transformation (Fig 3.12). In conclusion, this 
result shows that, while HRAS enhances cell survival, Nutlin-3a was able to reverse 
this acquired cancer hallmark. This finding, here is supported by previous studies that 
showed that Nutlin-3a decreased colony formation in DoHH2, MCA, OCI-LY3 and EJ 
cells (Drakos et al., 2011). 
MCF10A 
0h 
24h 
MCF10A 
HRAS  
MCF10A HRAS 
+ Nutlin-3a 
MCF10A + 
Nutlin-3a 
Figure 3. 2 Nutlin-3a reverses HRAS effect on cell migration through p53. Representative 
images showing the migration capability of HRAS with and without Nutlin-3a treatment on cells, 
using wound heling assay. Cell growth was monitored for one day. 
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Figure 3. 3 p53 activation reverses cell survival phenotype induced by 
HRAS transformation. Representative statistical analysis of the survival 
rate of HRAS transformed cells with or without Nutlin-3a treatment as 
measured using colony formation assay. Experiments were done in 
triplicates and the bars represent the standard error of the mean. 
 
3.4.4. Nutlin-3a reverses HRAS effect on mammosphere formation in 3D culture 
 
Disruption of cellular morphogenesis and organization is a hallmark of transformation. 
As we discussed above, HRAS transformation of MCF10A cells changed normal cell 
growth phenotypes. One of the normal cell growth phenotypes of MCF10A cells is 
their ability to form mammospheres in 3D cell culture setup. To test whether Nutlin-3a 
is capable of reversing the effect of HRAS overexpression on mammosphere 
formation, we cultured transformed and non-transformed MCF10A cells in Matrigel 
3D cell culture with and without Nutlin-3a treatment. Because Nutlin-3a leads to cell 
death, we used very low Nutlin-3a concentration for limited time to avoid cell death. 
This assay too, we were able to show that p53 can reverse the effect of HRAS 
transformation on mammosphere formation in vitro. As shown in Fig 3.13, MCF10A 
cells formed, as expected, very well organized mammospheres that resembles 
mammary gland cell growth in vivo (top most panel). Also, even though, smaller in 
size, MCF10A cells formed mammospheres after Nutlin-3a treatment (second panel 
from the top). On the other hand, upon transformation with HRAS, MCF10A cells 
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failed to form these regular mammospheres. On the contrary, these HRAS clones 
formed very big irregular masses of cells that lacked any organization (third panel from 
the top). However, upon Nutlin-3a treatment, HRAS clones were able to successfully 
grow in a very well organized mammospheres that recapitulated the normal growth of 
MCF10A before transformation (lower most panel).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
These results show that HRAS leads to the formation of disorganized clusters of 
MCF10A cells without central lumen formation and loss of polarity. This is in 
MCF10A HRAS 
MCF10A HRAS + 
Nutlin-3a 
MCF10A 
4 Days 7 Days 10 Days 
MCF10A + Nutlin-3a 
Figure 3. 4 p53 activation effect on mammosphere formation induced by HRAS 
transformation. Representative images at 20X shown the colony organization in 3D of HRAS with 
and without Nutlin-3a treatment on cells, using 3D culture assay. The mammosphere formation was 
monitored for 10 days. 
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concordance with a previous study which showed that HRAS transformation blocks 
normal luminal differentiation and dysregulated morphogenesis (Yu et al., 2009). 
Moreover, our results show that Nutlin-3a, by stabilizing p53, reverses the 
mammosphere organization to normal. This indicates that p53, by activating 
downstream pathway(s), is capable of reversing the imbalance of cellular hemostasis in 
the context of normal tissue development.   
 
3.4.5. Nutlin-3a effect on gene expression of p53 target genes 
 
To show that the genomic activity of p53 is rescued by Nutlin-3a, we measured the 
expression level of p53 direct target genes, p21 and BAX by RT-PCR with specific 
primers that shown. This regard, our results show that while HRAS transformation was 
able to reduce p21, and as expected (Y. Wang et al., 2013) increase BAX level. Nutlin-
3a was able to induce their p21 expression about 4 folds and server induce BAX level 
(Fig. 3.14 A&B). Overall, our gene expression results here, might explain some of the 
phenotypes induced by HRAS overexpression, like resistance to cell cycle arrest. BAX 
is a pro-apoptotic protein that when activated leads to cell death (Chipuk et al., 2004), 
while p21 is a cyclin dependent kinase inhibitor that leads to cell cycle arrest (Kachnic 
et al., 1999). Moreover, our data here prove that cell physiology reprogramming is 
dependent in part on transcriptional reprogramming that results from attenuating the 
function of important transcription factors like p53,  
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Figure 3. 5 Nutlin-3a rescues genomic p53 function. Real time PCR showing the effect of Nutlin-
3a on the expression of p53 target genes; p21 and BAX in HRAS transformed cells. In all figures, 
error bars represent the standard deviation of at least three different biological experiments done in 
triplicates.  
 
3.5.  Infected MCF10A HRAS with p63  
 
Throughout searching for the differential expression of different transcription factors between 
control and HRAS transformed cells, p63, a p53 homologue, was among the highly affected 
transcription factors (Salah et al un published data) and Fig3.15. Also , it was reported before 
that  HRAS overexpression in MCF10A cells  represses p63 transcription (Yoh et al., 2016).  
In order to evaluate the role of p63 in HRAS transformation, we generated MCF10A HRAS 
clones that overexpress p63 using a lentiviral vector using NOPLX305-TP63-HA-LRES-
PURO-K4 as transfer plasmid then selected by 1µg/µl Puromycin for 4-5 days. In order to 
test for the successful generation of these clones, we did RT- PCR using p63 specific primer 
(table 2.3) and hUBC one of the internal housing keep gene control. As our RT- PCR results 
show in Fig.3.15, indeed we were able to generate p63 clones that express ≈ 4 folds more 
p63 mRNA relative to control cells.   
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Figure 3. 6 Expression level of p63 in HRAS MCF10A p63 clones. Real 
time PCR results on mRNA extracted from the cells indicated in the graph. 
Error bars represent the standard error of the mean of three experiments 
done in triplicates. to defined the significances different between MCF10A 
HRAS and MCF10A HRAS TP63 cells by T-test to calculate p-value. (** 
means that p-value>0.05 and * means that p-value <0.05), to a significant 
results the p-value <0.05. 
 
 
3.6.  Characterization of p63 expression in HRAS transformed MCF10A cells   
 
After generating the p63 clones, we wanted to test the effect of p63 restoration on HRAS 
induced phenotypes. In order to do so, we tested some cell phenotypes known to be affected 
by oncogenic HRAS overexpression, including, cell proliferation, and cell migration, and 
genomic activity of p63. As shown in Fig. 3.16 A and B, using cell count and XTT cell 
proliferation assay, p63 cells have lower proliferative index compared to control cells. In 
HRAS clones, we noticed changes in cell morphology towards a more mesenchymal 
morphology that was accompanied with a more invasive potential (Fig 3.11). To evaluate the 
role of p63 in this acquired phenotype, we tested the migratory potential of p63 clones in 
wound healing assay. As shown in Fig.3.16 C, while HRAS were able to close the wound, 
p63 clones failed to do so, indicating that p63 clones are less migratory than HRAS clones. 
To assess p63 genomic function, the expression of p21 as a target p63 gene was evaluated. 
As shown in Fig 3.16 D using RT-PCR, HRAS transformed cells reduced p21 mRNA level 
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while p63 restored p21 expression in these cells. Altogether, our data here show that p63 
restoration in HRAS clones was able to reverse some cellular phenotypes related to HRAS 
transformation, which indicates that loss of p63 function plays a role in HRAS cell induced 
transformation. In comparison to p53 effects, p63 effects are mild. This is seen by not always 
having a very significant differences (p-value>0.05). These findings provide another 
evidence that changes in cellular phenotypes that accompany cellular transformation 
involves transcriptional reprogramming, that might be the heart of cell transformation into a 
cancer cell. 
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Figure 3. 7  Characterization of p63 clones. 
(A). Cell count assay showing the proliferation rate of the different cell clones indicated in the 
figure (B). XTT cell proliferation assay results showing the effect of p63 on HRAS clones growth rate 
over 3days. (B). Colony formation assay showing MCF10 cell survival rates after transforming cells with 
HRAS as compared with non-transformed cells. (C). Representative images of wound healing assay of 
different cell clones and control cells. (D). Real time PCR showing the effect of p63 on the expression of 
p63 target p21 in HRAS transformed cells. to defined the significances different between MCF10A HRAS 
and MCF10A HRAS TP63 cells by T-test to calculate p-value. (** means that p-value>0.05 and * means 
that p-value <0.05), to a significant results the p-value <0.05. 
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Chapter 4 
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
4. Conclusion  
 
A model that can be used for transformation-associated transcriptional reprogramming 
studying. Indeed; the data showed the successful ability to develop an in vitro model for 
studying transcriptional reprogramming of cellular transcription machinery and were able to 
identify important transcription factors involved in this reprogramming event. More important, 
the manipulation of these transcription factors were able to reverse in part some 
transformation-related phenotypes indicating that such a model can be used to identify 
important factors that can be utilized in breast cancer therapy or at least be utilized to identify 
biomarkers for breast cancer diagnosis or prognosis.   
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  ن اﻟﺜديﺎﻓﻲ ﺴرط اﻟﺠﻴﻨﻲ آﻟﻴﺎت ﺠدﻴدة ﻹﻋﺎدة ﺒرﻤﺠﺔ اﻟﻨﺴﺦﺘﺼﻤﻴم ﻨﻤوذج ﺨﻠوي ﻤن أﺠﻝ دراﺴﺔ 
  ﻋداد: ﻴوﺴف ﺴﻤﻴر اﺴﺤﺎق طرﻤﺎنإ
 اﺸراف: اﻟدﻛﺘور زﻴدون ﺼﻼح
  :ﺍﻟﻤﻠﺨﺺ
 
وﻴﻌد اﻟﻤﺴﺒب اﻻوﻝ ﻟوﻓﺎة اﻟﻨﺴﺎء اﻟﻼﺘﻲ  ،ﺴرطﺎن اﻟﺜدي ﻫو واﺤد ﻤن أﻛﺜر أﻨواع اﻟﺴرطﺎن ﺸﻴوﻋﺎ وﺘﻨوﻋﺎ 
وﻫذﻩ  ،ﻴﺘﺄﺜر ﺴرطﺎن اﻟﺜدي ﺒﻌواﻤﻝ داﺨﻠﻴﺔ  أو ﺨﺎرﺠﻴﺔ اﻟﻤﻨﺸﺄ. أﺼﺒن ﺒﺎﻟﺴرطﺎن ﻓﻲ ﺠﻤﻴﻊ أﻨﺤﺎء اﻟﻌﺎﻟم
أو اﻻﺜﻨﺘﻴن ﻤﻌﺎ ﻓﻲ   )noitatumipe(أو ﻓوق ﺠﻴﻨﻴﻪ )noitatum( ﻟﻰ طﻔرات ﺠﻴﻨﻴﻪااﻟﻌواﻤﻝ ﺘؤدي 
 romut(و اﻟﺠﻴﻨﺎت اﻟﻤﺜﺒطﺔ ﻟﻠﺴرطﺎنأ  )senegocno(ﺠﻴﻨﺎت ﻤﻬﻤﺔ وﺤﺴﺎﺴﺔ ﺘﺤﺘوي اﻟﺠﻴﻨﺎت اﻟﻤﺴرطﻨﺔ
ﻟﻰ اﻫذﻩ اﻟﺘﻐﻴرات ﻋﻠﻰ اﻟﻤﺴﺘوى اﻟﺠﻴﻨﻲ و اﻟﻔوق ﺠﻴﻨﻲ ﺘؤدي  أو اﻻﺜﻨﺘﻴن ﻤﻌﺎ. )seneg resserppus
ﺎء ﻫذﻩ اﻟﻤراﺤﻝ ﺘﻛﺘﺴب اﻟﺨﻼﻴﺎ ﺘﻐﻴرا وﺴوء ﺘﻨظﻴم ﻓﻲ ﻨﺸﺄة اﻟﺴرطﺎن وﺒﻌد ذﻟك اﻟﻰ ﺘﻘدم اﻟﺴرطﺎن. و ﻓﻲ أﺜﻨ
 ﻋﻠﻰ ﻤﺴﺘوﻴﺎت ﻤﺨﺘﻠﻔﺔ. و ﻴﻌد ﻤﺴﺘوى ﻨﺴﺦ اﻟﺠﻴﻨﺎت )noisserpxe eneg(اﻟﺘﻌﺒﻴر اﻟﺠﻴﻨﻲ
 اﻟﻤﺴﺘوﻴﺎت أﻫﻤﻴﺔ وﺤﺴﺎﺴﻴﺔ ﻋﻠﻰ ﺘﻐﻴرات اﻟﺘﻌﺒﻴر اﻟﺠﻴﻨﻲ ﻓﻲ اﻟﺴرطﺎن.  أﻛﺜر )noitpircsnart(
اﻓﺘرﻀﻨﺎ ﻓﻴﻪ أن اﻟﺘﺤوﻝ ﻟﺴرطﺎن اﻟﺜدي ﻗد ﻴﺘﺘﻀﻤن أﺤداﺜﺎ  ،ﻤﺸروﻋﻨﺎ اﻟﺤﺎﻟﻲ ﻫو ﺠزء ﻤن ﻤﺸروع ﻛﺒﻴر
ﻤﺸﺘرﻛﺔ ﻓﻲ إﻋﺎدة ﺘﻨظﻴم اﻟﻨﺴﺦ اﻟﺠﻴﻨﻲ. وﻫﻲ ﻤرﺘﺒطﺔ ﻤﻊ اﻟﺨﻠﻝ اﻟﺘﻨظﻴﻤﻲ ﻓﻲ اﻟﺘﻌﺒﻴر اﻟﺠﻴﻨﻲ اﻟذي ﻴﻨﻌﻛس 
ﻫدﻓﻨﺎ ﻓﻴﻪ ﻛﺎن اﺨﺘﺒﺎر ﻤﻘدرﺘﻨﺎ  ،ﻋﻠﻰ اﻟﻨﺸﺎط واﻟﺘوازن اﻟﺨﻠوي. وﻓﻲ ﻫذا اﻟﺠزء ﻤن اﻟﻤﺸروع اﻟذي أﻗدﻤﻪ ﻫﻨﺎ
ﺘﺤدﻴد ﻋواﻤﻝ اﻟﻨﺴﺦ اﺴﺘﺨدام ﻫذا اﻟﻨﻤوذج ﻟو  ،ﺜديﻨﺴﻴﺞ اﻟﻟ ﻲﺴرطﺎﻨاﻟﻋﻠﻰ اﻟﺘﺤوﻝ  ﻨﻤوذجﻋﻠﻰ إﻨﺸﺎء 
وﺘوظﻴﻔﻬﺎ ﻓﻲ اﻟﺘﺸﺨﻴص  واﻟوﻗﺎﻴﺔ أو ﻋﻠﻰ ﻤﺴﺘوى ﻋﻼج  ،اﻟﺠﻴﻨﻲ اﻟﺘﻲ ﻴﻤﻛن اﺴﺘﺨداﻤﻬﺎ ﻛﻌﻼﻤﺎت ﺤﻴوﻴﺔ
ﺘﺒر ﺴرطﺎن اﻟﺜدي. وﻤن أﺠﻝ اﻟوﺼوﻝ إﻟﻰ ﻫذﻩ اﻟﻨﻬﺎﻴﻪ ﻗﻤﻨﺎ ﺒﺈﻨﺸﺎء ﻨﻤوذج ﻟﺘﺤوﻝ ﺴرطﺎن اﻟﺜدي ﻓﻲ اﻟﻤﺨ
طﺒﻴﻌﻴﺔ  ،ﻓﻲ ﺨﻼﻴﺎ ﻤﺘﻤﺎﻴزة وﻏﻴر ﻤﺘﺤوﻟﺔ SARH )noisserpxerevo( ﻝ اﻟﺘﻌﺒﻴر ﻓﻲ اﻹﻓراط ﺒوﺴﺎطﺔ
اﻟﻤﻌروف ﺒﺄﻨﻪ ﻤن  ،ﻟﻠﺨﻠﻴﺔ ﻛﻤﺎ ﻗﻤﻨﺎ ﺒﻔﺤص ﻋدة طرز ﺸﻛﻠﻴﺔ .(A01FCMﻤن اﻟﻐدة اﻟﺜدﻴﻴﺔ ) طﻼﺌﻴﺔ
اﻟﺨﻼﻴﺎ  ﻫذﻩ اﺨﺘﺒﺎرﺘم  ﺜم .اﻟﻨﺎﺠﺢ اﻟﺘﺤوﻝ ﻀﻤﺎن؛ وذﻟك ﻤن أﺠﻝ  SARH ﻝ اﻟﺘﻌﺒﻴر ﻓﻲ اﻹﻓراط ﻴﺴﺒﺒﻬﺎ
ﻟﻔﺤص إﻋﺎدة ﺒرﻤﺠﺔ اﻟﻨﺴﺦ  ،)ﻟم ﻨﻘم ﻨﺤن ﺒﻬذا اﻟﺠزء ﻤن اﻟﻤﺸروع( ﻓﻲ ﺒﺤث ﻤﺘﻤم ﻟﻬذا اﻟﺒﺤث ،اﻟﻤﺘﺤوﻟﻪ
اﻟﺤﺠم ﻓﻲ اﻟواﻗﻊ أظﻬر ﻨﻤوذﺠﻨﺎ  .ﻤﺨﺘﻠﻔﺔ ﺘﻘﻨﻴﺎت مﺒﺎﺴﺘﺨدا.  )gnimargorper noitpircsnart(اﻟﺠﻴﻨﻲ
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اﻟﻨﺴﺦ اﻟﺠﻴﻨﻲ  ﻤواﻗﻊ ﺒﻴن ﻤﺨﺘﻠف .ﻋﻠﻰ ﻤﺴﺘوى اﻟﻤﺤﺘوى اﻟﺠﻴﻨﻲ ﺎتﻨﺴﺦ اﻟﺠﻴﻨﻓﻲ  ﺔﻋﺎدة ﺒرﻤﺠاﻟﻬﺎﺌﻝ ﻹ
ﻤن أﺠﻝ ﺘﻘﻴم دور ﻋواﻤﻝ اﻟﻨﺴﺦ اﻟﺠﻴﻨﻲ ﻫذﻩ ﻓﻲ . 36pو   35pﺔ ﻝ ﻨﺴﺦ اﻟﺠﻴﻨﻴاﻟﻤواﻗﻊ ﻛﺎﻨت اﻟﺘﻲ ﻓﻘدت 
ﻋﻦ  35p  ،ظﻬﺎر وظﺎﺌف ﻫذﻴن اﻟﻌﺎﻤﻠﻴن اﻟﻤﻬﻤﻴن ﻟﻠﻨﺴﺦ اﻟﺠﻴﻨﻲإ ﺈﻋﺎدةﻨﻤوذج اﻟﺘﺤوﻝ ﻫذا. ﻟﻘد ﻗﻤﻨﺎ ﺒ
ﻫﻨﺎ ﺘﺒﻴن أن ﺘﺤﻔﻴز  ،ﻋﻨﻪ. ﻨﺘﺎﺌﺠﻨﺎ اﻟﺘﻌﺒﻴر ﻲﻓ اﻹﻓراطﻋن طرﻴق  36p ﻭ a3-niltuNﻁﺮﻳﻖ ﺍﺳﺘﺨﺪﺍﻡ 
ﺤد ﻤﻌﻴن ﻻﻋﺎدة ﺒﻌض اﻟطرز اﻟﺸﻛﻠﻴﺔ اﻟﻤﺘﻌﻠﻘﺔ ﺒﻌﻤﻠﻴﺔ اﻟﺘﺤوﻝ  إﻟﻰوظﺎﺌف ﻋواﻤﻝ اﻟﻨﺴﺦ ﻫذﻩ ﻛﺎن ﻛﺎﻓﻴﺎ 
     .اﻟﻰ اﻟطرز اﻟﺸﻛﻠﻴﺔ ﻟﻠﺨﻼﻴﺎ ﻗﺒﻝ ﻋﻤﻠﻴﺔ اﻟﺘﺤوﻝ
ﻛﺄداة ﻓﻌﺎﻟﺔ ﻟﻠﺘﻌﻠم ﻋن إﻋﺎدة اﻟﺒرﻤﺠﺔ ﻟﻠﻨﺴﺦ اﻟﺠﻴﻨﻲ  اﻟﺨﺎص ﺒﻨﺎﻟﺘﺤوﻝ ا ﻴﻤﻛن اﺴﺘﺨدام ﻨﻤوذج ،ﻤﺠﺘﻤﻌﻪ
ﻗد ﺘﺴﺎﻫم رﺒﻤﺎ واﻟﺘﻲ  ،د دراﺴﺔ دور ﻋواﻤﻝ اﻟﻨﺴﺦ اﻟﺠﻴﻨﻲ اﻟﺨﺎﺼﺔ ﻓﻲ اﻟﺘﺤوﻝﻴوﺘﺤد ،ﺨﻼﻝ اﻟﺘﺤوﻝ اﻟﺨﻠوي
وﺘوظﻴﻔﻬﺎ ﻓﻲ اﻟوﻗﺎﻴﻪ واﻟﺘﺸﺨﻴص و  ،ﻓﻲ ﺘﺤدﻴد ﺒﻌض اﻟﺠﻴﻨﺎت اﻟﻤﺴﺘﻬدﻓﺔ اﻟﻤﺸﺎرﻛﺔ ﻓﻲ ﺴرطﺎن اﻟﺜدي
 اﻟﻌﻼج.
 
 
 
 
 
 
